Filtered By:
Cancer: HER2

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 260 results found since Jan 2013.

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.
Authors: Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Déas O, Cairo S, Judde JG, Tagliabue E, Iorio MV Abstract Trastuzumab is the standard treatment for HER2+ breast cancer (BC) patients, and even though it significantly improved their clinical outcome, 50% of them do not benefit from this drug and disease recurs, underlining the need of reliable predictive biomarkers and new therapeutic strategies. Strikingly, despite all the molecular analyses performed to identify the escape mechanisms behind this resistance, it still represents a question point. MiRNAs have been correl...
Source: Oncotarget - July 4, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells.
Abstract Exosomes are the best options for gene targeting, because of their natural, nontoxic, non-immunogenic, biodegradable, and targetable properties. By engineering exosome-producing cells, ligands can be expressed fusing with exosomal surface proteins for targeting cancer cell receptors. In the present study, HER2-positive breast cancer cells were targeted with a modified exosome producing engineered HEK293T cell. For this purpose, the HEK293T cells were transduced by a lentiviral vector bearing-LAMP2b-DARPin G3 chimeric gene. Stable cells expressing the fusion protein were selected, and the exosomes produced...
Source: Applied Biochemistry and Biotechnology - June 28, 2018 Category: Biochemistry Authors: Limoni SK, Moghadam MF, Moazzeni SM, Gomari H, Salimi F Tags: Appl Biochem Biotechnol Source Type: research

Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.
Authors: Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ Abstract In patients with HER2-expressing breast cancer many develop resistance to HER2 targeted therapies. We show that high and intermediate HER2-expressing cancer cell lines are driven toward apoptosis and tumor senescence when treated with either CD4+ Th1 cells, or Th1 cytokines TNF-α and IFN-γ, in a dose dependent manner. Depletion of HER2 activity by either siRNA or trastuzumab and pertuzumab, and subsequent treatment with either anti-HER2 Th1 cells or TNF-α and IFN-γ resulted in synergistic increased tumor senes...
Source: Oncotarget - May 31, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
CONCLUSIONS We found that elevated levels of pSphK1 were positive correlation with high expression of S1P, which in turn promoted metastasis of TNBC through S1P/S1PR3/Notch signaling pathway. PMID: 29605826 [PubMed - in process]
Source: Medical Science Monitor - April 3, 2018 Category: Research Tags: Med Sci Monit Source Type: research

GSE111246 HER2 Overexpression Modifies the Cellular Response to Hypoxia in MCF7 Breast Cancer Cell Lines
Contributor : Edward J JarmanSeries Type : Expression profiling by arrayOrganism : Homo sapiensTumour hypoxia is a recognised driver of breast cancer pathology. The main cellular response to hypoxia is mediated by the hypoxia-inducible factors HIF1 and HIF2, and is controlled through the regulation of oxygen-labile HIF α subunits. HIF1α has a well-established role in breast cancer where it has also been shown to be regulated by growth factor signalling. However, the role of HIF2α has been less thoroughly researched. Here, the role of HIF2α was investigated in breast cancer cell lines and publicly available gen e expres...
Source: GEO: Gene Expression Omnibus - March 1, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
In this study we aimed to identify mechanisms of resistance to SRC inhibitors in ovarian cancer cells. Using two complementary strategies; a targeted tumour suppressor gene siRNA screen, and a phospho-receptor tyrosine kinase array, we demonstrate that activation of MAPK signalling, via a reduction in NF1 (neurofibromin) expression or overexpression of HER2 and the insulin receptor, can drive resistance to AZD0530. Knockdown of NF1 in two ovarian cancer cell lines resulted in resistance to AZD0530, and was accompanied with activated MEK and ERK signalling. We also show that silencing of HER2 and the insulin receptor can pa...
Source: Oncotarget - February 14, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

GSE109798 Comparative Transcriptomics of Triple Negative Breast Cancer Stem Cells and Differentiated Tumor Cells Identifies Teneurin-4 as a Potential Therapeutic Target
CONCLUSIONS: Overall, our results indicate that the stem-like status of TNBC cells is accompanied by altered regulation of apoptosis, cell cycle and lipid metabolism pathways. Furthermore, we identified TENM4 as a potential novel player in CSC biology, and its potential role as a novel target to improve the outcome of TNBC patients in the future.
Source: GEO: Gene Expression Omnibus - January 30, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Mus musculus Source Type: research

Suppression of Kpn β1 expression inhibits human breast cancer cell proliferation by abrogating nuclear transport of Her2.
In this study, we identified karyopherin β-1 (Kpnβ1) as a possible novel therapeutic target for BC. Western blotting was used to evaluate the expression of Kpnβ1 in four pairs of tumorous and adjacent non-tumorous tissues. The results revealed that the protein level of Kpnβ1 was higher in the cancer samples compared with those in the corresponding normal samples. Immunohistochemistry was performed on 140 BC cases and indicated that Kpnβ1 was significantly associated with clinical pathological variables. Kaplan-Meier curve revealed that high expression of Kpnβ1 was related to poor BC patient prognosis. A starvation a...
Source: Oncology Reports - December 19, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells
Conclusions The mechanism for foretinib growth inhibition in MET-amplified EAC tumor cells is demonstrated. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2.
Source: The Annals of Thoracic Surgery - December 7, 2017 Category: Cardiovascular & Thoracic Surgery Source Type: research

HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
CONCLUSIONS: The mechanism for foretinib growth inhibition in MET-amplified EAC tumor cells is demonstrated. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2. PMID: 29223420 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - December 6, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL Tags: Ann Thorac Surg Source Type: research

Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells
ConclusionsBased on our results we conclude that AREG is involved in regulating the proliferation and migration of erbB2/HER2-positive breast cancer cells.
Source: Cellular Oncology - November 27, 2017 Category: Cancer & Oncology Source Type: research

t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
CONCLUSIONS: t-Darpp activates IGF-1R signaling through heterodimerization with EGFR and HER2 to stimulate glycolysis and confer trastuzumab resistance. PMID: 29180608 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 27, 2017 Category: Cancer & Oncology Authors: Lenz G, Hamilton A, Geng S, Hong T, Kalkum M, Momand J, Kane SE, Huss J Tags: Clin Cancer Res Source Type: research

Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor.
Authors: Tiash S, Kamaruzman NIB, Chowdhury EH Abstract Cancer cells lose their control on cell cycle by numerous genetic and epigenetic alterations. In a tumor, these cells highly express growth factor receptors (GFRs), eliciting growth, and cell division. Among the GFRs, epidermal growth factor receptor-1 (EGFR1) (Her1/ERBB1) and epidermal growth factor receptor-2 (EGFR2) (Her2/ERBB2) from epidermal growth factor (EGF) family and insulin-like growth factor-1 receptor (IGF1R) are highly expressed on breast cancer cells, thus contributing to the aggressive growth and invasiveness, have been focused in this study. M...
Source: Drug Delivery - November 10, 2017 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells.
Authors: Zeng X, Che X, Liu YP, Qu XJ, Xu L, Zhao CY, Zheng CL, Hou KZ, Teng Y Abstract Trastuzumab has been widely applied as a treatment for human epidermal growth factor 2 (HER2)-overexpressing breast cancer. However, the therapeutic efficacy of trastuzumab is limited. Flap endonuclease 1 (FEN1) is a multifunctional endonuclease that has a crucial role in DNA recombination and repair. Inhibition of FEN1 is associated with the reversal of anticancer drug resistance. However, it is unclear whether FEN1 is involved in trastuzumab resistance. In the present study, it was demonstrated that trastuzumab increases the e...
Source: Experimental and Therapeutic Medicine - September 17, 2017 Category: General Medicine Tags: Exp Ther Med Source Type: research

Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
CONCLUSIONS: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1. PMID: 28910818 [PubMed - as supplied by publisher]
Source: Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Oki E, Okano S, Saeki H, Umemoto Y, Teraishi K, Nakaji Y, Ando K, Zaitsu Y, Yamashita N, Sugiyama M, Nakashima Y, Ohgaki K, Oda Y, Maehara Y Tags: Oncology Source Type: research